Increased CSF-decorin predicts brain pathological changes driven by Alzheimer’s Aβ amyloidosis
Authors:
Open Access
- 4 July 2022
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 10 (1) , 1-17
Abstract
Cerebrospinal fluid (CSF) biomarkers play an important role in diagnosing Alzheimer’s disease (AD) which is characterized by amyloid-β (Aβ) amyloidosis. Here, we used two App knock-in mouse models, AppNL-F/NL-F and AppNL-G-F/NL-G-F, exhibiting AD-like Aβ pathology to analyze how the brain pathologies translate to CSF proteomes by label-free mass spectrometry (MS). This identified several extracellular matrix (ECM) proteins as significantly altered in App knock-in mice. Next, we compared mouse CSF proteomes with previously reported human CSF MS results acquired from patients across the AD spectrum. Intriguingly, the ECM protein decorin was similarly and significantly increased in both AppNL-F/NL-F and AppNL-G-F/NL-G-F mice, strikingly already at three months of age in the AppNL-F/NL-F mice and preclinical AD subjects having abnormal CSF-Aβ42 but normal cognition. Notably, in this group of subjects, CSF-decorin levels positively correlated with CSF-Aβ42 levels indicating that the change in CSF-decorin is associated with early Aβ amyloidosis. Importantly, receiver operating characteristic analysis revealed that CSF-decorin can predict a specific AD subtype having innate immune activation and potential choroid plexus dysfunction in the brain. Consistently, in AppNL-F/NL-F mice, increased CSF-decorin correlated with both Aβ plaque load and with decorin levels in choroid plexus. In addition, a low concentration of human Aβ42 induces decorin secretion from mouse primary neurons. Interestingly, we finally identify decorin to activate neuronal autophagy through enhancing lysosomal function. Altogether, the increased CSF-decorin levels occurring at an early stage of Aβ amyloidosis in the brain may reflect pathological changes in choroid plexus, present in a subtype of AD subjects.Keywords
Funding Information
- Bertil Hållstens Forskningsstiftelse
- Alzheimerfonden
- Hjärnfonden
- Vetenskapsrådet
- Karolinska Institute
This publication has 50 references indexed in Scilit:
- A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid βScience Translational Medicine, 2012
- Involvement of JNK in the regulation of autophagic cell deathOncogene, 2010
- A highly insoluble state of Aβ similar to that of Alzheimer's disease brain is found in Arctic APP transgenic miceNeurobiology of Aging, 2009
- Blood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysisNeurobiology of Aging, 2009
- A facile method for expression and purification of the Alzheimer’s disease‐associated amyloid β‐peptideThe FEBS Journal, 2009
- Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2008
- Megalin mediates the transport of leptin across the blood-CSF barrierNeurobiology of Aging, 2008
- The Arctic Alzheimer mutation facilitates early intraneuronal Aβ aggregation and senile plaque formation in transgenic miceNeurobiology of Aging, 2006
- Macroautophagy—a novel β-amyloid peptide-generating pathway activated in Alzheimer's diseaseJournal of Cell Biology, 2005
- Peripheral distribution of dermatan sulfate proteoglycans (decorin) in amyloid-containing plaques and their presence in neurofibrillary tangles of Alzheimer's disease.Journal of Histochemistry & Cytochemistry, 1992